Usona Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 2014-01-01

Employees: 11

Market Cap: -

Website: http://www.usonainstitute.org

Clinical Trials

Psilocybin for Major Depressive Disorder (MDD)

Phase 3

Recruiting

Conditions: Depressive Disorder, Major

Interventions: Drug: Psilocybin 25 mg
Drug: Psilocybin 5 mg
Drug: Inactive Placebo
Behavioral: Psychosocial Support

First Posted Date: 2024-03-13

Last Posted Date: 2024-12-03

Lead Sponsor: Usona Institute

Target Recruit Count: 240

Registration Number: NCT06308653

Locations: 🇺🇸
University of Alabama Clinical Research Unit, Birmingham, Alabama, United States
🇺🇸
Preferred Research Partners-NWA, LLC, Fayetteville, Arkansas, United States
🇺🇸
Preferred Research Partners, Inc., Little Rock, Arkansas, United States

and more 21 locations

Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers

Phase 1

Completed

Conditions: Pharmacokinetics
Safety
Tolerability

Interventions: Drug: 5-methoxy-N,N-dimethyltryptamine succinate salt
Drug: Placebo

First Posted Date: 2023-01-26

Last Posted Date: 2023-11-30

Lead Sponsor: Usona Institute

Target Recruit Count: 54

Registration Number: NCT05698095

Locations: 🇺🇸
Altasciences Clinical Kansas, Inc, Overland Park, Kansas, United States

An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics

Phase 1

Completed

Conditions: QTc Interval
Pharmacokinetics

Interventions: Drug: Micro-Crystalline Cellulose
Drug: Moxifloxacin
Drug: Psilocybin

First Posted Date: 2022-07-28

Last Posted Date: 2023-08-15

Lead Sponsor: Usona Institute

Target Recruit Count: 60

Registration Number: NCT05478278

Locations: 🇺🇸
Altasciences Clinical Kansas, Inc, Overland Park, Kansas, United States

PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder

Terminated

Conditions: Major Depressive Disorder

Interventions: Other: No intervention will be administered as part of this study.

First Posted Date: 2020-04-21

Last Posted Date: 2022-12-02

Lead Sponsor: Usona Institute

Target Recruit Count: 24

Registration Number: NCT04353921

Locations: 🇺🇸
Segal Trials, Lauderhill, Florida, United States

A Study of Psilocybin for Major Depressive Disorder (MDD)

Phase 2

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Psilocybin
Drug: Niacin
Other: Set and Setting (SaS) Protocol

First Posted Date: 2019-03-07

Last Posted Date: 2023-06-05

Lead Sponsor: Usona Institute

Target Recruit Count: 104

Registration Number: NCT03866174

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Cedar Clinical Research, Draper, Utah, United States
🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States

and more 8 locations

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy